Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer
Background: Bevacizumab has been increasingly used in combination chemotherapy with paclitaxel for treatment of metastatic or recurrent breast cancer. The aim of this report is to underline possible risks associated with the new combination chemotherapy. Case Presentation: A 39-year-old woman with r...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2013-01-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | http://www.karger.com/Article/FullText/346839 |
_version_ | 1819017135311028224 |
---|---|
author | Yoshie Nakayama Yoshinori Ito Masahiko Tanabe Shunji Takahashi |
author_facet | Yoshie Nakayama Yoshinori Ito Masahiko Tanabe Shunji Takahashi |
author_sort | Yoshie Nakayama |
collection | DOAJ |
description | Background: Bevacizumab has been increasingly used in combination chemotherapy with paclitaxel for treatment of metastatic or recurrent breast cancer. The aim of this report is to underline possible risks associated with the new combination chemotherapy. Case Presentation: A 39-year-old woman with recurrent breast cancer was treated with bevacizumab and paclitaxel. Positron emission tomography revealed breast cancer metastasis to the left supraclavicular lymph nodes and right axillary lymph nodes, with no distant metastasis. Results: After the third cycle of bevacizumab and paclitaxel, the patient developed a bloody bowel discharge. Emergent colonoscopy demonstrated diverticular bleeding on one of the multiple diverticula in the ascending colon. The bleeding point was successfully clipped colonoscopically. Conclusion: The factors for diverticular bleeding are believed to be non-steroidal anti-inflammatory drugs, constipation, and bevacizumab. We recommend reviewing anamneses for diverticulitis, multiple prior abdominal surgeries, peritoneal carcinomatosis, and regular use of certain drugs. |
first_indexed | 2024-12-21T02:58:43Z |
format | Article |
id | doaj.art-773b6e3da848427f8cba96ebbbe8897e |
institution | Directory Open Access Journal |
issn | 1662-6575 |
language | English |
last_indexed | 2024-12-21T02:58:43Z |
publishDate | 2013-01-01 |
publisher | Karger Publishers |
record_format | Article |
series | Case Reports in Oncology |
spelling | doaj.art-773b6e3da848427f8cba96ebbbe8897e2022-12-21T19:18:14ZengKarger PublishersCase Reports in Oncology1662-65752013-01-0161505410.1159/000346839346839Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast CancerYoshie NakayamaYoshinori ItoMasahiko TanabeShunji TakahashiBackground: Bevacizumab has been increasingly used in combination chemotherapy with paclitaxel for treatment of metastatic or recurrent breast cancer. The aim of this report is to underline possible risks associated with the new combination chemotherapy. Case Presentation: A 39-year-old woman with recurrent breast cancer was treated with bevacizumab and paclitaxel. Positron emission tomography revealed breast cancer metastasis to the left supraclavicular lymph nodes and right axillary lymph nodes, with no distant metastasis. Results: After the third cycle of bevacizumab and paclitaxel, the patient developed a bloody bowel discharge. Emergent colonoscopy demonstrated diverticular bleeding on one of the multiple diverticula in the ascending colon. The bleeding point was successfully clipped colonoscopically. Conclusion: The factors for diverticular bleeding are believed to be non-steroidal anti-inflammatory drugs, constipation, and bevacizumab. We recommend reviewing anamneses for diverticulitis, multiple prior abdominal surgeries, peritoneal carcinomatosis, and regular use of certain drugs.http://www.karger.com/Article/FullText/346839Opioid analgesicsBreast cancerBevacizumabPaclitaxelAdverse effectsDiverticular bleedingNon-steroidal anti-inflammatory drugs |
spellingShingle | Yoshie Nakayama Yoshinori Ito Masahiko Tanabe Shunji Takahashi Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer Case Reports in Oncology Opioid analgesics Breast cancer Bevacizumab Paclitaxel Adverse effects Diverticular bleeding Non-steroidal anti-inflammatory drugs |
title | Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer |
title_full | Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer |
title_fullStr | Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer |
title_full_unstemmed | Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer |
title_short | Diverticular Bleeding of the Colon during Combination Chemotherapy with Bevacizumab and Paclitaxel for Recurrent Breast Cancer |
title_sort | diverticular bleeding of the colon during combination chemotherapy with bevacizumab and paclitaxel for recurrent breast cancer |
topic | Opioid analgesics Breast cancer Bevacizumab Paclitaxel Adverse effects Diverticular bleeding Non-steroidal anti-inflammatory drugs |
url | http://www.karger.com/Article/FullText/346839 |
work_keys_str_mv | AT yoshienakayama diverticularbleedingofthecolonduringcombinationchemotherapywithbevacizumabandpaclitaxelforrecurrentbreastcancer AT yoshinoriito diverticularbleedingofthecolonduringcombinationchemotherapywithbevacizumabandpaclitaxelforrecurrentbreastcancer AT masahikotanabe diverticularbleedingofthecolonduringcombinationchemotherapywithbevacizumabandpaclitaxelforrecurrentbreastcancer AT shunjitakahashi diverticularbleedingofthecolonduringcombinationchemotherapywithbevacizumabandpaclitaxelforrecurrentbreastcancer |